



**Certificate of Mailing 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **MAIL STOP MISSING PARTS**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Signing Certificate: Sheryl Neumann

December 16, 2003  
Date

Sheryl Neumann  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Named Inventor:	Bernhard KEPPLER	§	
		§	
		§	
Conf. No.:	2897	§	Group Art Unit: Not Yet Assigned
		§	
Appln. No.:	10/627,519	§	Examiner: Not Yet Assigned
		§	
Filing Date:	July 25, 2003	§	Attorney Docket No.: 8182-25US
		§	(PA32424US)
Title:	COMPOSITIONS CONTAINING A RUTHENIUM(III) COMPLEX AND A HETEROCYCLE		

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)**

Enclosed are copies of each of the documents listed on the attached Information Disclosure Citation Form(s) PTO/SB/08A and/or B, which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

The enclosed references were cited in a German Office Action dated October 24, 2001 (copy enclosed) from the German Patent Office in counterpart German Application No. 101 03 565.9-47 and/or were cited and discussed at pages 1 and 2 of the present specification.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against

interest in any manner.


No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the merits. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A and/or B be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Bernhard KEPPLER

December 15, 2003  
(Date)



William W. Schwarze  
Attorney/Agent for Applicant(s)  
Registration No. 25,918  
Direct Dial: 215-965-1270  
E-Mail: wschwarze@akingump.com

Akin Gump Strauss Hauer & Feld LLP  
One Commerce Square  
2005 Market Street, Suite 2200  
Philadelphia, PA 19103  
Telephone No.: 215-965-1200  
Fax No.: 215-965-1210

WWS:srn  
Enclosures



Form <b>PTO/SB/08A</b>		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/627,519
		<b>Filing Date</b>	July 25, 2003
		<b>First Named Inventor</b>	Bernhard KEPPLER
		<b>Group Art Unit</b>	Not Yet Assigned
		<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	1	<b>of</b>	1
		<b>Attorney Docket Number</b>	8182-25US (PA32424US)

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code	Number	Kind Code (if known)		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		
	F. KRALIK et al., "Complex compounds of trivalent ruthenium with pyrazol and imidazol", <i>Collection Czechoslov. Chem. Commun.</i> , Vol. 26, pp. 1298-1304, (1961).		
	B.K. KEPPLER et al., "Synthesis Molecular Structure, and Tumor-Inhibiting Properties of Imidazolium trans-Bis(imidazole)tetrachlororuthenate(III) and Its Methyl-Substituted Derivatives", <i>Inorg. Chem.</i> , Vol. 26, pp. 4366-4370, (1987).		
	MARTIN R. BERGER et al., "Efficacy of New Ruthenium Complexes against Chemically Induced Autochthonous Colorectal Carcinoma in Rats", <i>Anticancer Res.</i> , Vol. 9, pp. 761-766, (1989).		
	E. ALESSIO et al., "Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(II) Complexes: Synthesis, Structural Characterization, and Reactivity of Ru(CO) <sub>x</sub> (DMSO) <sub>4-x</sub> C1 <sub>2</sub> Complexes (x=1-3)", <i>Inorg. Chem.</i> , Vol. 34, pp. 4722-4734, (1995).		
	WOLFGANG PETI et al., "Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt", <i>Eur. J. Inorg. Chem.</i> , pp. 1551-1555, (1999).		
	B.K. KEPPLER et al., "New Tumor-Inhibiting Metal Complexes. Chemistry and Antitumor Properties", <i>Met-Based Drugs</i> , Vol. 1, Nos. 2-3, pp. 145-150, (1994).		
	MATTHIAS H. SEELIG et al., "Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats", <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 118, No. 3, pp. 195-200, (1992).		
	MICHAEL J. CLARK, "The Potential of Ruthenium in Anticancer Pharmaceuticals", <i>American Chemical Society Symp. Ser.</i> , pp. 157-180 (1980).		

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--